Everything below concerns tesamorelin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
=== Pathogens === E-liquid used in e-cigarettes has been found to be contaminated with fungi and bacteria. Nicotine-containing e-liquids are extracted from tobacco that may contain impurities. Tobacco-specific impurities such as cotinine, nicotine-N'-oxides (cis and trans isomers), and beta-nornicotyrine are believed to be the result of bacterial action or oxidation during the extraction of nicotine from tobacco.
==== Cylindrical spirals myopathy ==== Cylindrical spirals myopathy is very rare with only 18 individual cases described as of 2013. The majority of cases are sporadic, and has been observed in only 3 families. It is characterized by the presence of cylindrical spirals as the main pathological finding in muscle biopsies. Cylindrical spirals are unusual membrane structures that have a spiral pattern. These membrane structures are seen during electron microscopic examination of the affected muscle. These structures merge into or are surrounded by tubular structures that resemble tubular aggregates. Tubular aggregates are abnormal accumulations of membranous tubules and have been observed in a wide variety of muscle diseases and originate from the sarcoplasmic reticulum. Cylindrical spirals were first described in 1979 and were thought to be a non-specific reaction of skeletal muscle secondary to a metabolic disturbance or muscle fibre injury. The molecular basis of cylindrical spiral myopathy is currently unknown, however a genetic mutation affecting the sarcoplasmic reticulum in some patients seems likely, as SERCA1, calsequestrin, and RYR1 have been shown to bind to cylindrical spirals. Cylindrical spirals have also been shown to react with the mitochondrial enzyme succinate dehydrogenase, which suggests that cylindrical spirals originate from mitochondria. Phenotypes are quite variable, and manifestations can include weakness, abnormal gait, myotonia, cramps, and scoliosis.
1993/1887) Occupational Pension Schemes (Public Service Pension Schemes) (Amendment) Regulations 1993 (S.I. 1993/1888) Magistrates' Courts Fees (Amendment) Order 1993 (S.I. 1993/1889) Medicines (Products Other Than Veterinary Dmgs) (Prescription Only) Amendment Order 1993 (S.I. 1993/1890) Colleges of Further Education (Changes of Names) (Scotland) Order 1993 (S.I. 1993/1891) Education (Access Funds) (Scotland) Amendment Regulations 1993 (S.I. 1993/1892) Offshore Installations (Safety Zones)(No. 3) Order 1993 (S.I. 1993/1893) Assisted Areas (Amendment) Order 1993 (S.I. 1993/1894) Legal Aid in Criminal and Care Proceedings (General) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/1895) Neath—Abergavenny Trunk Road (A465) (Improvement from Aberdulais to Glynneath, Aberdulais Slip Roads) Order 1993 (S.I. 1993/1896) Management and Administration of Safety and Health at Mines Regulations 1993 (S.I. 1993/1897) Poultry Breeding Flocks and Hatcheries Order 1993 (S.I. 1993/1898) Meat and Livestock Commission Levy (Variation) Scheme (Confirmation) Order 1993 (S.I. 1993/1899)
Sources: en.wikipedia.org
=== 2-D liquid chromatography === By coupling liquid chromatography with a variety of other immunodetection techniques such as serological proteome analysis (SERPA), it is possible to analyze the hydrophobicity, PI, relative mass, and antibody reactivity of antibodies within a given serum.
Alice in Chains (often abbreviated as AiC) is an American rock band formed in Seattle in 1987. Since 2006, the band's lineup has consisted of vocalist/guitarists Jerry Cantrell and William DuVall, bassist Mike Inez, and drummer Sean Kinney. Original vocalist Layne Staley died in 2002, and former bassist Mike Starr left in 1993. Often associated with grunge music, Alice in Chains' sound and style is rooted in heavy metal. The band is known for its distinctive vocal style, which often included the harmonized vocals between Staley and Cantrell (and later Cantrell and DuVall). Alice in Chains' original lineup consisted of Cantrell, Kinney, Staley, and Starr. They took the name from Staley's previous band, Alice N' Chains. The band rose to international fame as part of the grunge movement of the early 1990s, along with other Seattle bands such as Nirvana, Pearl Jam, and Soundgarden. They broke through on MTV and mainstream rock radio with the single "Man in the Box" (from their 1990 debut album Facelift). After releasing the EP Sap in early 1992, the band achieved major mainstream and commercial success with their follow-up album Dirt later that same year. Dirt contained the popular singles "Rooster" and "Would?", among others. Starr was replaced on bass by Inez in early 1993. The following two records, 1994's Jar of Flies (which included the popular single "No Excuses") and 1995's Alice in Chains (also contained radio hits such as "Heaven Beside You" and "Grind"), both topped the US Billboard 200 chart and earned the band several Grammy Award nominations.
Interpreting pet food labels – Pet food labeling according to AAFCO regulations National Research Council (U.S.). Subcommittee on Dog Nutrition (1974). Nutrient requirements of dogs. National Academy of Sciences. ISBN 978-0-309-02315-3.
Sources: en.wikipedia.org
A positive correlation has been observed between the degree of aggregation and cytotoxic potential, with CNT agglomerates exhibiting greater toxicity than CNT bundles. Agglomerated CNTs tend to form larger, more rigid, and compact structures—morphologically similar to asbestos fibers—compared to the more loosely associated CNT bundles. Specifically, agglomerated SWCNTs have been shown to induce pronounced granulomatous inflammation, characterized by granuloma formation surrounded by hypertrophic macrophages in seven days post-exposure. In contrast, well-dispersed SWCNTs elicit significantly milder inflammatory responses. Impurities: Metal contaminants of CNT materials are strongly associated with the induction of oxidative stress and proinflammatory responses, with toxicity levels closely correlated to metal content. Among them, iron is a potent catalyst for intracellular reactive oxygen species generation, disrupting iron homeostasis and promoting oxidative damage. Nickel exhibits high bioactivity and proinflammatory potential. The underlying mechanism is thought to involve lysosomal membrane destabilization, leading to the release of cathepsin B and subsequent activation of the NLRP3 inflammasome pathway. Beyond metal impurities, the presence of non-metallic contaminants, including amorphous carbon and other carbonaceous byproducts (e.g., polycyclic aromatic hydrocarbons can significantly modulate the biological response to CNTs, contributing to cytotoxicity and inflammatory signaling.
Stephanie Kate Howard, Moves and Operations Manager, Buckingham Palace Re-servicing Programme, Royal Household. Adelaide Georgina Gray Izat, Paintings Conservator, Royal Collection, Royal Household. Daniel James Kevin Johnson, Archbishop of Canterbury's Coronation Planning Director, on the occasion of the Coronation of Their Majesties The King and The Queen. Kevin Malkin, Detective Constable, Metropolitan Police Service. For services to Royalty Protection. Louise Michelle Walker-Pickett, Purchasing and Cost Control Co- ordinator, Royal Household. Nicola Jane Pritchard, Property Project Manager, Windsor Castle. Warrant Officer Class 1 David Alexander Roper, Grenadier Guards, 25131200; Superintending Clerk, Household Division, on the occasion of the Coronation of Their Majesties The King and The Queen. Warrant Officer Class 2 Julian Philip Desmond Sandford, Royal Corps of Army Music, 25152991; Sergeant Major, Band of the Household Cavalry, on the occasion of the Coronation of Their Majesties The King and The Queen. Christopher Charles Savage, lately Messenger Sergeant Major, The King's Body Guard of the Yeomen of the Guard. Derrick Andrew Scott, Royal Borough of Windsor and Maidenhead, on the occasion of the Coronation Concert. Thomas Nicholas McKinlay Service, lately Acting Chief Operating Officer, Household of The Prince and Princess of Wales. Elizabeth Fiona St Clair, Sergeant, Metropolitan Police Service. For services to Royalty and Specialist Protection. Kathryn Elizabeth Stone, Paper Conservator, Royal Collection, Royal Household.
== Budget == For the 2026 fiscal year, CLIA was budgeted US$25.2 million. The approximately 86 surveyors conduct 120 surveys annually, 112 initial/recertification and eight follow-up surveys, spending an average of up to 14 hours per survey. The staffing ratio is one clerk per three surveyors, one professional support staff per six surveyors, and one supervisory surveyor per seven surveyors. The projected workload is 7,933 compliance initial and recertification surveys, 2505 follow-up/revisit surveys of compliance laboratories, 393 validations of accredited laboratories, 92 follow-up/revisit surveys of accredited laboratories, 215 complaint surveys, and 725 proficiency testing desk reviews. The Waived Laboratory Survey Initiative is discontinued, and CLIA waivers are no longer available; PPM laboratories will not receive routine inspections.
==== Elimination ==== Instead of by hepatic metabolism, atenolol is eliminated from the blood mainly via renal excretion. Atenolol is excreted about 40 to 50% in urine and 50% in feces with oral administration. Conversely, it is excreted 85 to 100% in urine unchanged and 10% in feces with intravenous administration. Only very small amounts of hydroxyatenolol and atenolol glucuronide are found in urine with atenolol. The elimination half-life of atenolol is about 6 to 7 hours. The half-life of atenolol does not change with continuous administration. With intravenous administration, atenolol levels rapidly decline (5- to 10-fold) during the first 7 hours and thereafter decline at a rate similar to that with oral administration. The elimination of atenolol is slowed in renal impairment, with the elimination rate being closely related to the glomerular filtration rate (GFR) and with significant accumulation occurring when the creatinine clearance rate is under 35 mL/min/1.73 m2. At a GFR of less than 10 mL/min, the half-life of atenolol increases up to 36 hours.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
Lyophilized material is typically kept refrigerated and away from light in the sealed vial provided. Dissolved material is generally used within a limited period rather than stored long term.